[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Francis Farhadi\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":191},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,73,95,115,136,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100652713","lumbar-fusion-with-nanotube-vs-titanium-cage-100652713",false,"NCT07777718","Lumbar Fusion With Nanotube Versus Titanium Cage","Nanotube Surface Architecture Versus Simple Titanium Coating on PEEK Interbody Cages in Adults Undergoing 1- and 2-Level Transforaminal Lumbar Interbody Fusion: A Randomized Controlled Superiority Trial","Inclusion Criteria:\n\n* Subject is scheduled to undergo 1- or 2-level TLIF with the principal investigator.\n* Subject has failed nonoperative management for a minimum of 3 months prior to enrollment.\n* Diagnosis is degenerative disc disease (DDD), defined as discogenic back pain with disc degeneration confirmed by history and radiographic studies, at 1 or 2 contiguous spinal levels from L2 to S1. Subjects may have up to grade 1-2 spondylolisthesis or retrolisthesis at the index level(s).\n* Subject is able to provide written informed consent.\n* Subject is, in the investigator's opinion, psychosocially, mentally, and physically able to comply with the protocol, required follow-up visits, and completion of required study forms.\n\nExclusion Criteria:\n\n* Prior lumbar arthrodesis surgery at any level.\n* Diagnosis of osteoporosis (T-score = -2.5) or severe osteopenia (T-score = -2.0 with fragility fracture history).\n* Body mass index (BMI) greater than 40 kg\u002Fm².\n* Requirement for additional bone grafting materials beyond milled local autograft bone (e.g., rhBMP-2, iliac crest autograft, allograft structural spacers).\n* Active local or systemic infection.\n* Known metal sensitivity or foreign body reaction to titanium or PEEK.\n* Active malignancy or history of spinal malignancy.\n* Known diabetes mellitus with preoperative HbA1c =8%, confirmed within 90 days of the planned surgery date. Diabetic patients with HbA1c \\\u003C8% are eligible following standard preoperative medical optimization.\n* Condition requiring medications known to interfere with bone healing (chronic oral or parenteral glucocorticoids, immunosuppressives, bisphosphonates initiated within 3 months of surgery, methotrexate, or similar agents).\n* Inadequate tissue coverage over the operative site or open wound at the operative area.\n* Pregnancy or planned pregnancy within the next 12 months, or currently lactating.\n* Current involvement in litigation or receipt of Worker's Compensation related to back or leg pain.\n* Current enrollment in another investigational drug or device study that could confound study data.\n* History (present or past) of substance abuse that, in the investigator's opinion, would interfere with protocol adherence or follow-up completion.\n* Any medical condition or extenuating circumstance that, in the opinion of the investigator, would preclude safe participation in the study.\n* Subject is a prisoner.","ALL","18 Years","80 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is comparing two FDA-approved cages used during lower back surgery. The study will look at whether one cage helps the bones in the back fuse together better than the other. Adults who are having a 1 or 2 level lumbar fusion surgery will be randomly assigned to receive either the Adaptix nanoPEEK cage or the Capstone PTC cage. Participants will have follow-up visits with imaging and questionnaires to evaluate bone fusion, back and leg pain, physical function, and overall health.",[27,28],"Degenerative Disc Disease","Lumbar Fusion","NOT_YET_RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":21},"2026-09",{"date":37,"type":21},"2028-04-30",{"name":39,"class":40},"Francis Farhadi","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100556048","evaluating-safety-and-feasibility-of-transcutaneous-spinal-cord-stimulation-following-traumatic-and-non-traumatic-spinal-cord-injury-a-pilot-study-100556048","NCT06520020","Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study","STIM","Inclusion Criteria:\n\n* Age: = 18 years and = 80 years.\n* Written informed consent by patient and\u002For legal authorized representative (LAR).\n* No other life-threatening condition.\n* No evidence of sepsis.\n* No evidence of superficial skin infection at site of surgery and intervention.\n* An established diagnosis of either:\n\n  * cervical myelopathy with modified Japanese Orthopaedic Association score of 8-14, or\n  * acute cervical \u002F thoracic SCI with ASIA Impairment Scale grade A-D (as assessed within 72 hours of injury) with neurologic level of injury (NLI) from C2 to T12.\n* The ability to undergo, or have had, surgical intervention. -. The ability to undergo transcutaneous intervention including study procedures in the posterior cervical or thoracic midline at or after 14 days from surgery.\n\nExclusion Criteria:\n\n* Any concomitant impairment of the upper and lower limb at baseline that could potentially confound the neurologic assessments; including but not limited to traumatic or disease conditions like brachial plexus injury, peripheral neuropathy, spinal hematoma, transverse myelitis, non-compressive myelopathy, dementia, and Parkinson's disease.\n* mJOA of \\>= 15 and \\\u003C= 7, or AIS grade E tSCI at baseline assessment.\n* Currently involved in another non-observational ntSCI or tSCI study, or receiving another interventional drug, that could interfere with recordings and confound adverse events.\n* Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation, at discretion of the treating surgeon and\u002For principal investigator.\n* Unable to commit to the follow-up schedule.\n* Recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study.\n* Any condition likely to result in the patient's death within the next 12 months.\n* Prisoner.\n* Pregnancy.\n* Cardiac pacemaker dependent, unable to undergo electrical stimulation.\n* Brain implant, skull prosthesis, plate and screws limiting transcranial stimulation.\n* Tattoo at site of skin electrode that causes heat\u002Fpain during stimulation.\n* Subjects who in the opinion of the investigator are not suitable for inclusion in the study, with reason documented.",{"count":50,"type":21},30,[24],"The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups:\n\n1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention.\n2. Early tSCI screened during the hospital admission when cervical\u002Fthoracic spinal injury was diagnosed.\n3. Delayed tSCI (control) screened 6-24 months after acute cervical\u002Fthoracic spinal injury.",[54,55,56,57],"Spinal Cord Stimulation","Electric Stimulation Therapy","Traumatic Spinal Cord Injury","Cervical Myelopathy",[59,60,61,62,63],"Stimulation","Transcutaneous","MagStim","Transcranial","Magnetic","RECRUITING","2026-07-02",{"date":67,"type":33},"2026-07-07",{"date":69,"type":33},"2024-10-23",{"date":71,"type":21},"2027-12-01",{"name":39,"class":40},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100474926","prospective-analysis-of-spinal-epidural-abscess-100474926","NCT05464251","Prospective Analysis of Spinal Epidural Abscess","Prospective Analysis of Spinal Epidural Abscess Associated Outcomes at the University of Kentucky","SEA","Inclusion Criteria:\n\n* All patient with ICD codes for pyogenic vertebral osteomyelitis, discitis, and spinal epidural abscess will be reviewed for inclusion.\n\nExclusion Criteria:\n\n* Patients unwilling or unable to attend follow up appointments.",{"count":82,"type":21},200,"OBSERVATIONAL","This is a prospective study involving all patients treated at the University of Kentucky for spinal epidural abscess over a 2-year period. Based on ongoing referrals of patients with SEA, we expect that 200 patients will be enrolled during this time window. We propose to study all available clinical, pathological, radiological, and socioeconomic data of patients diagnosed with a spinal infection with or without a history of drug abuse over this study period. All patients' charts will be prospectively reviewed starting at the time of presentation for a period of 1 year.",[86],"Spinal Epidural Abscess","2026-02-10",{"date":89,"type":33},"2026-02-13",{"date":91,"type":33},"2022-07-12",{"date":93,"type":21},"2027-06",{"name":39,"class":40},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":106,"studyType":83,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":41},"100473543","degenerative-cervical-myelopathy-repository-100473543","NCT05446259","Degenerative Cervical Myelopathy Repository","Development of a Predictive Outcome Model for Patients With Degenerative Cervical Myelopathy Using Objective Functional and Biological Measures.","DCM","Inclusion Criteria:\n\n* Diagnosis of degenerative cervical myelopathy\n* Diagnosis of cervical degenerative disease without myelopathy\n\nExclusion Criteria:\n\n* None outside or diagnostic requirements and age limits.","100 Years",{"count":105,"type":21},245,"2 Years","To create a research repository of patients with known degenerative cervical myelopathy (DCM) and a control cohort of subjects who have non-myelopathic spinal disease. This repository will be used to assess functional and\u002For biological measures that may allow for improved prediction of symptomatic progression and response to treatment in patients with DCM. In addition, this repository will be used to develop a risk assessment scale to accurately predict functional outcomes following operative management of DCM.",[57],{"date":89,"type":33},{"date":111,"type":33},"2022-07-13",{"date":113,"type":21},"2028-05",{"name":39,"class":40},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":41},"100472038","phase-1-spinal-cord-injury-neuroprotection-with-glyburide-100472038","NCT05426681","Spinal Cord Injury Neuroprotection With Glyburide","Spinal Cord Injury Neuroprotection With Glyburide (SCING): Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury","SCING","Inclusion Criteria:\n\n* No life threatening injuries resulting from the traumatic accident\n* No evidence of sepsis\n* Acute cervical or thoracic SCI with ASIA Impairment Scale Grade A, B, or C od admission.\n* Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12\n\nExclusion Criteria:\n\n* Unconsciousness or other mental impairment that prevents neurological assessment within the first 8 hours\n* Acute SCI with ASIA Impairment Scale grade D or E\n* Currently involved in another non-observational SCI research study or receiving another investigational drug\n* History of hypersensitivity to sulfonylureas, in particular glyburide, or any of its components\n* Any condition likely to result in the patient's death within the next 12 months\n* Severe renal disorder from the patient's history (e.g. dialysis) or baseline eGFR of \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Known severe liver disease, or ALT \\> 3 times upper limit of normal or bilirubin\n* Blood glucose \\\u003C55 mg\u002FdL at enrollment or immediately prior to administration of DiaBeta, or a clinically significant history of hypoglycemia\n* Acute ST elevation myocardial infarction, and\u002For acute decompensated heart failure, and\u002For QTc \\> 520 ms, and\u002For known history of cardiac arrest (PEA, VT, VF, asystole), and\u002For admission for an acute coronary syndrome, myocardial infarction, or coronary intervention (percutaneous coronary intervention or coronary artery surgery) within the past 3 months\n* Known G6PD enzyme deficiency",true,{"count":125,"type":21},12,[127],"PHASE1","To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.",[130],"Acute Spinal Cord Injury",{"date":89,"type":33},{"date":133,"type":33},"2022-07-07",{"date":113,"type":21},{"name":39,"class":40},{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":41},"100534775","spinal-decompression-plus-nerve-graft-implantation-following-tsci-100534775","NCT06243211","Spinal Decompression Plus Nerve Graft Implantation Following TSCI","Minimizing Secondary Injury in Patient With SCI Using Expansive Duroplasty","Inclusion Criteria:\n\n* Age: = 18 years and = 80 years\n* Written informed consent by patient or legal authorized representative\n* No other life-threatening injury\n* No evidence of sepsis\n* Acute cervical or thoracic SCI with ASIA Impairment Scale grade A or B on admission\n* Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12\n* The ability to undergo surgical intervention including study procedures through a posterior approach within 48 hours of injury\n\nExclusion Criteria:\n\n* Unconsciousness or other mental impairment that prevents neurological assessment within the first 48 hours\n* Acute SCI with ASIA Impairment Scale grade C, D or E\n* Spinal cord decompression and spinal stabilization can be safely performed through an anterior-only approach (i.e. posterior approach is not required)\n* Currently involved in another non-observational SCI research study or receiving another investigational drug\n* Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation (at discretion of the principal investigator)\n* Unable to commit to the follow-up schedule\n* A recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study\n* Any condition likely to result in the patient's death within the next 12 months\n* Prisoner\n* Subjects who in the opinion of the investigator are not suitable for inclusion in the study (reason to be documented).\n* Pregnancy",{"count":144,"type":21},10,[24],"This is a single-blinded (with outcome assessors blinded to treatment allocation), 12-month pilot study to evaluate of the safety, feasibility, and preliminary efficacy of dorsal myelotomy and expansive duraplasty performed either without or with autologous nerve graft implantation after acute traumatic spinal cord injury.\n\nTen participants will be allocated to receive either DMED (n=5) or DMED + ANGI (n=5) based on a block design. Participants and assessors will be blinded to group allocation. Excess sural nerve samples will be collected for banking\u002Fanalysis (may include proteomic, culturing, genomic, cellular analysis).",[148,149],"Spinal Cord Injuries","Acute Traumatic Spinal Cord Injury",[151,152,153,154,155],"Decompression","Dorsal","Duraplasty","Myelotomy","Nerve Graft","2025-12-03",{"date":158,"type":33},"2025-12-10",{"date":160,"type":33},"2024-04-19",{"date":162,"type":21},"2026-12-31",{"name":39,"class":40},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":171,"targetDuration":173,"studyType":83,"phases":4,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":41},"100467390","thoracic-lumbar-arthrodesis--implanet-jazz-100467390","NCT05366140","Thoracic-Lumbar Arthrodesis- Implanet Jazz","Prospective Follow-up of Patients Undergoing Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz System TM.","Inclusion Criteria:\n\n* Male and female patients, 18 years of age and older\n* Qualified candidate for hybrid thoracolumbar fixation with the Implanet Jazz System TM during arthrodesis surgery.\n\nExclusion Criteria:\n\n* Individuals who have not yet reached the age of 18.",{"count":172,"type":21},300,"5 Years","Establish a data repository of patients who have undergone single, two-, or three-level lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System.",[176,177,178],"Spondylolisthesis","Spinal Stenosis","Degenerative Disease",[180,181,182],"Thoracic-Lumbar Arthrodesis","Spinal fusion","back pain","2025-10-23",{"date":185,"type":33},"2025-10-27",{"date":187,"type":33},"2022-02-03",{"date":189,"type":21},"2028-09",{"name":39,"class":40},""]